Haematologica
HAEMATOL/2019/222299
Version 3

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

Lene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, Bronno van der Holt, Ulf-Henrik Mellqvist, Morten Salomo, Gerard Bos, Mark-David Levin, Heleen Visser-Wisselaar, Markus Hansson, Annette van der Velden, Wendy Deenik, Juleon Coenen, Maja Hinge, Saskia Klein, Bea Tanis, Damian Szatkowski, Rolf Brouwer, Matthijs Westerman, Rineke Leys, Harm Sinnige, Einar Haukås, Klaas van der Hem, Marc Durian, Peter Gimsing, Niels van de Donk, Pieter Sonneveld, Anders Waage, Niels Abildgaard, and Sonja Zweegman

Disclosures: AW reports that the study was supported by Celgene and receives honoraria from Takeda and grant from Amgen. MH reports compensation for work related to the study from NTNU Department of Cancer Research and Molecular Medicine and receives grant from Celgene Aps. MS receives personal fees from Celgene, Amgen, Janssen and Takeda. SZ receives research funding from Celgene, Janssen, Takeda and Amgen and serves on advisory board for Celgene, Janssen, Takeda and Amgen. NA receives research funding from Celgene, Janssen, Takeda and Amgen. LKN has received grants from Celgene, Janssen, Amgen and Takeda, during the conduct of the study. M-DL has received personal fees from Celgene. U-HM has received lecture honoraria from Amgen, Takeda, Janssen, Mundipharma, Oncopeptides and serves on advisory board for Amgen. NvdD receives grants from Celgene, Janssen pharmaceuticals, Novatis, Amgen and BMS and serves at the advisory board for Celgene, Janssen pharmaceuticals, Novartis, Amgen, Takeda, BMS, Bayer, Servier. All other authors declare no conflicting interest.

Contributions: SZ, AW, PS, GB, U-HM, BvdH, NA, LKN and CS participated in planning and designing the study. LKN, CS, U-HM, MS, GB, MD-L, MH, AvdV, WD, JC, MH, SK, BT, DS, RB, MW, RL, HS, EH, KvdH, MD, PG, NvdD, PS, AW, NA, SZ contributed to patient recruitment. DS, HV-W, KvdH, NvdD, RL, U-HM, MW, EH, MHa, MS contributed to data collection. CS, DS, LKN and SZ contributed to literature search. HV-W contributed to coordination of data cleaning process and trial management of the study. BLW, BvdH, CS, U-HM, LKN, NA, SZ contributed to data analyses. BLW, CS, LKN, BvdH, NA and SZ contributed to data interpretation. LKN, CS, U-HM, MS, GB, MD-L, MH, AvdV, WD, JC, MH, SK, BT, DS, RB, MW, RL, HS, EH, KvdH, MD, PG, NvdD, PS, AW, NA, SZ contributed to manuscript writing.